Indonesia Primary Cells Market Outlook to 2028

Indonesia Primary Cells Market Overview

The Indonesia Primary Cells Market has shown a notable growth, as evidenced by the global primary cells market reaching a valuation of USD 1.5 billion in 2023. This growth is primarily driven by the increasing demand for primary cells in medical research and biotechnology applications. The rise in chronic diseases and the need for advanced treatment options have accelerated the adoption of primary cells for research purposes.

The primary cells market in Indonesia is dominated by several key players, including Thermo Fisher Scientific, Merck KGa A, Lonza Group, Cell Applications, and Promo Cell Gmb H. These companies have established a strong presence in the market through extensive product offerings, continuous innovations, and strategic collaborations with research institutions and healthcare providers.

In 2023, Thermo Fisher Scientific announced the expansion of its primary cells product line in Indonesia, introducing advanced cell culture technologies to support cutting-edge research in oncology and regenerative medicine. This development aims to meet the growing demand for high-quality primary cells and enhance the company's market share in the region .

In 2023, Jakarta was dominating the primary cells market due to its advanced healthcare infrastructure and concentration of leading research institutions. The presence of top universities, research centers, and biotechnology firms in the city has significantly contributed to its dominant position in the market.

Indonesia Primary Cells Market Segmentation

The Indonesia Primary Cells Market can be segmented into three major segmentations which are as follows:

By Product Type: The Indonesia Primary Cells Market is segmented by product type into human primary cells, animal primary cells, and stem cells. In 2023, human primary cells held a dominant market share due to their extensive use in biomedical research and drug development. The increasing prevalence of chronic diseases and the need for personalized medicine have driven the demand for human primary cells. Furthermore, advancements in cell isolation and culture techniques have enhanced the availability and quality of human primary cells, contributing to their dominance in the market.

By Application: The Indonesia Primary Cells Market is segmented by application into cancer research, vaccine production, and drug discovery. In 2023, cancer research was the leading application segment, driven by the high incidence of cancer in Indonesia and the ongoing efforts to develop effective treatments. The increasing investment in oncology research and the adoption of advanced cell culture technologies have fueled the growth of this segment. Additionally, the government's focus on enhancing cancer research capabilities has further supported the dominance of this application.

By Region: Indonesia Primary Cells Market is segmented by region into North, South, East, and West. In 2023, the North region was dominating due to its advanced healthcare infrastructure and concentration of leading research institutions. The presence of top universities, research centers, and biotechnology firms in the city has significantly contributed to its dominant position in the market. Furthermore, government initiatives to enhance research capabilities in the region have bolstered its market share.

Indonesia Primary Cells Market Competitive Landscape

Indonesia Primary Cells Market Major Players

Company Name

Establishment Year

Headquarters

Thermo Fisher Scientific

1956

Waltham, MA, USA

Merck KGa A

1668

Darmstadt, Germany

Lonza Group

1897

Basel, Switzerland

Cell Applications

1994

San Diego, CA, USA

Promo Cell Gmb H

1990

Heidelberg, Germany

Thermo Fisher Scientific: In 2024, Thermo Fisher Scientific, the global leader in serving science, will significantly expand its operations in Indonesia by opening its first official office in Jakarta in April, marking a key milestone in supporting the country's advancement in healthcare, clean energy, biopharma, and food safety, according to Sho-Wen Yeo, vice president and general manager of Southeast Asia & Taiwan.

Lonza and Integral Molecular’s Strategy: In 2022, Lonza and Integral Molecular announced a strategy to offer complementary expertise in assessing the potential for off-target binding and activation of biologic drug candidates, to enhance early de-risking of biotherapeutics. In June 2024, new product is launched by Lonza introduced its new Capsugel Enprotect capsule in a smaller 9 format for delivering acid-sensitive APIs.

Indonesia Primary Cells Market Analysis

Indonesia Primary Cells Market Growth Drivers

Increased Healthcare Expenditure: The country witnessed healthcare expenditure of around IDR 312.4 trillion in the year 2021 and this expenditure on healthcare is expected to reach IDR 450 trillion by 2024, driven by government initiatives to improve healthcare infrastructure and accessibility. This surge in spending is expected to boost the demand for primary cells, as hospitals and research institutions invest in advanced cell culture technologies to enhance medical research and treatment outcomes.

Rising Prevalence of Chronic Diseases: The prevalence of chronic diseases such as diabetes and cancer are increasing in Indonesia, with projected number of over 10 million people being diagnosed with diabetes in 2024. This growing health burden necessitates extensive research into disease mechanisms and treatments, driving the demand for primary cells in biomedical research and drug development.

Government Funding for Biomedical Research: In 2024, the Indonesian government allocated IDR 150 billion for biomedical research, focusing on cancer and infectious diseases. This funding supports the establishment of research centers and the procurement of primary cells, which are essential for conducting high-quality research and developing innovative therapies.

Indonesia Primary Cells Market Challenges

High Cost of Primary Cells: The high cost is a barrier for smaller research institutions and laboratories, limiting their access to essential research materials. The financial burden of acquiring primary cells can hinder the progress of various research projects, affecting overall market growth and innovation. Researchers often struggle to balance their budgets while ensuring the procurement of high-quality cells necessary for advanced biomedical studies.

Lack of Skilled Personnel: Despite the rapid growth of the biotechnology sector, there is a notable shortage of skilled personnel proficient in advanced cell culture techniques in Indonesia. In 2024, the workforce in the biotech industry had the necessary training and expertise to handle primary cells effectively. This skill gap poses a significant challenge to the market, as it impacts the efficiency and quality of research outcomes. The lack of adequately trained professionals can lead to suboptimal use of primary cells, thereby limiting the potential advancements in biomedical research.

Indonesia Primary Cells Market Government Initiatives

National Biomedical Research Initiative: In 2024, the Indonesian government launched a National Biomedical Research Initiative with a budget of IDR 150 billion. This initiative aims to establish state-of-the-art research facilities and provide grants for advanced research in oncology and infectious diseases, thereby boosting the demand for primary cells.

Healthcare Transformation Program: The Ministry of Health in Indonesia has introduced a six-pillar healthcare transformation plan which was launched in 2020 and covers the time period of 2020-2024. The plan emphasizes various aspects of healthcare improvement, including technology and infrastructure development. The Asian Development Bank (ADB) has provided a $350 million loan to support this transformation, specifically targeting the enhancement of primary care services. This funding will facilitate the integration of health information systems and improve the capacity of healthcare providers through training and better equipment.

Indonesia Primary Cells Market Future Outlook

The Indonesia Primary Cells Market is expected to grow exponentially by 2028. The market future growth will be driven by technological advancements in cell culture techniques, increased investment in biomedical research, and the rising prevalence of chronic diseases necessitating advanced treatment modalities.

Market Trends

Advancements in Cell Culture Technologies: Over the next five years, advancements in cell culture technologies will significantly impact the Indonesia primary cells market. Researchers are expected to develop more efficient and cost-effective methods for culturing primary cells, leading to higher adoption rates and improved research outcomes.

Development of Personalized Medicine: The growing focus on personalized medicine will boost the demand for primary cells in Indonesia. By 2028, personalized medicine is expected to become a standard approach in treating chronic diseases, necessitating extensive research using primary cells to develop tailored therapies.
Please Note: It will take 5-7 business days to complete the report upon order confirmation